ArticleBioinformation2025
A typical presentation of AMSAN variant of guillain-barré syndrome in an elderly female with multisystem involvement: A case report.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré Syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy, with the AMSAN (Acute Motor and Sensory Axonal Neuropathy) variant representing a severe subtype characterized by rapid progression and poor prognosis. This report describes a 68-year-old woman presenting with progressive quadriparesis, cranial nerve involvement, and bowel and respiratory complications, ultimately diagnosed as AMSAN based on nerve conduction studies and cerebrospinal fluid analysis. MRI and EEG findings contributed to the diagnostic complexity due to age-related degenerative and vascular changes. Despite early IVIg administration, the patient required intensive care, emphasizing the need for prompt diagnosis and multidisciplinary management. AMSAN in elderly patients demands high clinical vigilance and early neurophysiological evaluation to initiate timely immunotherapy and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.